Kazia Therapeutics Limited (KZIA) 6-K/A 9 Mar 23 2023 Q2 2. Results for announcement to the market Financial data

Cover

Cover	6 Months Ended
	Dec. 31, 2022
Document Information [Line Items]
Document Type	6-K/A
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Registrant Name	Kazia Therapeutics Limited
Entity Central Index Key	0001075880
Current Fiscal Year End Date	--06-30

Statement of profit or loss and

Statement of profit or loss and other comprehensive income - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue and other income
Other income	$ 0	$ 24,956
Finance Income	139	1,989
Expenses
Research and development expense	(9,359,972)	(10,988,075)
General and administrative expense	(4,276,514)	(2,482,582)
Loss on revaluation of contingent consideration	(85,226)	(74,110)
Loss before income tax benefit	(13,721,573)	(13,517,822)
Income tax benefit	135,546	315,974
Loss after income tax benefit for the half-year attributable to the owners of Kazia Therapeutics Limited	(13,586,027)	(13,201,848)
Items that may be reclassified subsequently to profit or loss
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax	86,494	6,946
Other comprehensive income for the half-year, net of tax	86,494	6,946
Total comprehensive income for the half-year attributable to the owners of Kazia Therapeutics Limited	$ (13,499,533)	$ (13,194,902)
Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited
Basic earnings per share	$ (9.327)	$ (10)
Diluted earnings per share	$ (9.327)	$ (10)

Statement of financial position

Statement of financial position - AUD ($)	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 4,390,523	$ 7,361,112	$ 15,188,957
Trade and other receivables	741,128	90,975
Other	784,557	156,153
Total current assets	5,916,208	7,608,240
Non-current assets
Intangibles	18,204,147	19,138,858
Trade and other receivables	3,715,248	7,300,870
Total non-current assets	21,919,395	26,439,728
Total assets	27,835,603	34,047,968
Current liabilities
Trade and other payables	3,148,768	3,760,120
Borrowings	552,315	0
Employee benefits	442,835	166,196
Contingent consideration	1,438,461	758,840
Total current liabilities	5,582,379	4,685,156
Non-Current liabilities
Deferred tax	2,424,815	2,560,361	2,928,441
Employee benefits	126,907	318,983
Contingent consideration	8,118,317	8,208,945
Total non-current liabilities	10,670,039	11,088,289
Total liabilities	16,252,418	15,773,445
Net assets	11,583,185	18,274,523
Equity
Contributed equity	90,343,718	84,480,249
Reserves	3,439,399	2,411,665
Accumulated losses	(82,199,932)	(68,617,391)
Total equity	$ 11,583,185	$ 18,274,523	$ 25,315,899

Statement of changes in equity

Statement of changes in equity - AUD ($)	Total	Contributed equity [member]	Other Contributed equity [member]	Reserves [member]	Foreign currency translation reserve [Member]	Accumulated Losses [member]
Beginning Balance (Previously stated [member]) at Jun. 30, 2021	$ 37,850,719	$ 80,290,062	$ 464,000	$ 1,753,886	$ (453,320)	$ (44,203,909)
Beginning Balance (Adjustment for correction of error [member]) at Jun. 30, 2021	2,476					2,476
Beginning Balance at Jun. 30, 2021	37,853,195	80,290,062	464,000	1,753,886	(453,320)	(44,201,433)
Loss after income tax benefit for the half-year | Previously stated [member]	(13,022,408)
Loss after income tax benefit for the half-year	(13,201,848)					(13,201,848)
Other comprehensive income for the half-year, net of tax	6,946				6,946
Total comprehensive income for the half-year	(13,194,902)				6,946	(13,201,848)
Transactions with owners in their capacity as owners:
Immaterial reclassification					(433,333)	433,333
Exercise of options	16,700	16,700		(5,622)		5,622
Employee share-based payment options - expired				(159,142)		159,142
Employee share-based payment options	640,906			640,906
Ending balance at Dec. 31, 2021	25,315,899	80,306,762	464,000	2,230,028	(879,707)	(56,805,184)
Beginning Balance (Previously stated [member]) at Jun. 30, 2022	18,638,287	84,480,249		3,263,703	(852,038)	(68,253,627)
Beginning Balance (Adjustment for correction of error [member]) at Jun. 30, 2022	(363,764)					(363,764)
Beginning Balance at Jun. 30, 2022	18,274,523	84,480,249		3,263,703	(852,038)	(68,617,391)
Loss after income tax benefit for the half-year	(13,586,027)					(13,586,027)
Other comprehensive income for the half-year, net of tax	86,494				86,494
Total comprehensive income for the half-year	(13,499,533)				86,494	(13,586,027)
Issue of shares	6,263,986	6,263,986
Share issue costs	(400,517)		(400,517)
Transactions with owners in their capacity as owners:
Employee share-based payment options - expired				(3,486)		3,486
Employee share-based payment options	944,726			944,726
Ending balance at Dec. 31, 2022	$ 11,583,185	$ 90,744,235	$ (400,517)	$ 4,204,943	$ (765,544)	$ (82,199,932)

Statement of cash flows

Statement of cash flows - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Payments to suppliers (inclusive of GST)	$ (8,806,148)	$ (11,391,410)
Net cash used in operating activities	(8,806,148)	(11,391,410)
Cash flows from investing activities
Payment of milestone relating to contingent consideration	0	(1,582,278)
Net cash used in investing activities	0	(1,582,278)
Cash flows from financing activities
Proceeds from issue of shares (net of costs)	5,850,869	16,700
Net cash from financing activities	5,850,869	16,700
Net decrease in cash and cash equivalents	(2,955,279)	(12,956,988)
Cash and cash equivalents at the beginning of the financial half-year	7,361,112	27,586,760
Effects of exchange rate changes on cash and cash equivalents	(15,310)	559,185
Cash and cash equivalents at the end of the financial half-year	$ 4,390,523	$ 15,188,957

Significant accounting policies

Significant accounting policies	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Significant accounting policies	Note 1. Significant accounting policies These general purpose financial statements for the interim half-year These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated. New or amended Accounting Standards and Interpretations adopted The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Going concern During the half year ended 31 December 2022 the consolidated entity experienced net cash outflows from operating activities of $8,806,148 (December 2021: $11,391,410) and incurred a loss after tax of $13,586,027 (December 2021 restated: $13,201,848). As at 31 December 2022 the consolidated entity had cash in hand and at bank of $4,390,523. The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. An ‘at-the-market’ equity program (ATM) with Oppenheimer & Co. Inc. (Oppenheimer), as sales agent was established in May 2022. Under the ATM, Kazia may offer and sell via Oppenheimer up to US$35 million of its ordinary shares, in the form of American Depository Shares (ADSs), with each ADS representing ten ordinary shares. Kazia entered into an Equity Distribution Agreement, dated 22 April 2022 (the Sales Agreement), with Oppenheimer, who acts as sales agent. As at 31 December 2022 net proceeds of A$9,560,357 have been raised. On 3 January 2023 a deposit of US$428,096 was received from Labcorp Early Development Laboratories Inc. representing the refund due on the completion of the Paxalisib Phase II trial. On 1 Accordingly the directors have prepared the financial statements on a going concern basis. While the Company’s current cash balance is not sufficient to fund the operations for a period of 12 months from the date of this report, the directors have prepared the financial statements on a going concern basis as they are confident of the Company’s ability to raise additional funding, via licensing and partnering activities, obtaining of grant funding or raising additional capital from investors. Should the above assumptions not prove to be appropriate, there is material uncertainty related to events or conditions that may cast significant doubt whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements.

Critical accounting judgements,

Critical accounting judgements, estimates and assumptions	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Critical accounting judgements, estimates and assumptions	Note 2. Critical accounting judgements, estimates and assumptions When preparing the half-year financial statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management and will seldom equal the estimated results. The judgments, estimates and assumptions applied in the half-year

Restatement of comparatives

Restatement of comparatives	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Restatement of comparatives	Note 3. Restatement of comparatives Correction of error During the December 2022 review, the calculation of the EVT-801 asset and its contingent consideration was found to contain errors as discounting for the time value of money was not taken into account on initial recognition. The contractual payments in relation to the milestones gave rise to a financial liability at acquisition. The cost of the intangible asset should comprise the initial payment plus an amount reflecting the fair value of the other contingent payments determined using a probability–weighted estimation. These values should be discounted to reflect the time value of money at the time of acquisition in April 2021. Management have utilised an Incremental Borrowing Rate of 6% to discount the future cash flows. The Incremental Borrowing Rate reflects the assumed credit rating of the Company. The error resulted in a material overstatement of the EVT-801 asset and a corresponding overstatement of the liability at acquisition. The impact of this error is noted below with the restated balances disclosed in note 10,14 and 16: 30 June 2022 Increase/ 30 June 2022 Restated Intangibles - licensing agreement EVT-801 10,857,763 (1,044,401 ) 9,813,362 Less Accumulated amortisation (1,049,555 ) 133,641 (915,914 ) 9,808,208 (910,760 ) 8,897,448 Current contingent consideration EVT-801 (758,840 ) — (758,840 ) Non-Current contingent consideration EVT-801 (7,588,405 ) 546,996 (7,041,409 ) (8,347,245 ) 546,996 (7,800,249 ) Net Assets 18,638,287 (363,764 ) 18,274,523 Accumulated losses (68,253,627 ) (363,764 ) (68,617,391 ) Total equity 18,638,287 (363,764 ) 18,274,523 Consolidated statement of profit and loss 31 December (Increase)/ 31 December Restated Research and development expense (Amortisation) (11,029,851 ) 41,776 (10,988,075 ) General and administrative expense (interest and foreign exchange impact) (2,261,366 ) (221,216 ) (2,482,582 ) Loss before tax (13,338,382 ) (179,440 ) (13,517,822 ) Income tax benefit 315,974 — 315,974 Loss after tax (13,022,408 ) (179,440 ) (13,201,848 ) Impact on basic and diluted earnings per share increase/(decrease) in earning per share Cents Cents Cents Basic loss for the year attributable to equity holders (9.864 ) (0.136 ) (10.000 ) Diluted loss for the year attributable to equity holders (9.864 ) (0.136 ) (10.000 )

Operating segments

Operating segments	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Operating segments	Note 4. Operating segments Identification of reportable operating segments The consolidated entity’s operating segment is based on the internal reports that are reviewed and used by the Board of Directors (being the Chief Operating Decision Makers (‘CODM’)) in assessing performance and in determining the allocation of resources. The information reported to the CODM, on at least a quarterly basis, is the consolidated results as shown in the statement of profit or loss and other comprehensive income and statement of financial position.

Other income

Other income	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Other income	Note 5. Other income Consolidated December 2022 December 2021 $ $ Government grants — 10,000 Bad debt recovery — 14,956 Other income — 24,956

Expenses

Expenses	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Expenses	Note 6. Expenses Consolidated December 2022 $ December 2021 Restated * $ Loss before income tax includes the following specific expenses: Amortisation Paxalisib licensing agreement 542,177 542,177 EVT-801 licensing agreement 392,534 392,534 Total amortisation 934,711 934,711 Interest expense Contingent consideration 221,637 207,068 Superannuation expense Defined contribution superannuation expense 63,734 93,960 Employee benefits expense excluding superannuation Employee benefits expense excluding superannuation 1,778,503 1,349,523

Cash and cash equivalents

Cash and cash equivalents	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Cash and cash equivalents	Note 7. Cash and cash equivalents Consolidated December 2022 June 2022 $ $ Cash at bank and on hand 4,390,523 7,361,112

Trade and other receivables

Trade and other receivables	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Trade and other receivables	Note 8. Trade and other receivables Consolidated December 2022 June 2022 $ $ GST refundable 69,093 51,353 Paxalisib Phase II clinical trial refund 631,876 — 700,969 51,353 Deposit paid 40,159 39,622 741,128 90,975 The Paxalisib Phase II clinical trial refund is the amount owing (US$428,096) from Labcorp Early Development Laboratories Inc. after their final reconciliation of trial costs. Funds were received on 3 January 2023.

Other assets

Other assets	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Current assets - other	Note 9. Other assets Consolidated December 2022 June 2022 $ $ Prepayments 784,557 156,153

Intangibles

Intangibles	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Intangibles	Note 10. Intangibles Consolidated December 2022 June 2022 Restated * $ $ Paxalisib Licensing agreement - at acquired fair value 16,407,788 16,407,788 Less: Accumulated amortisation (6,708,555 ) (6,166,378 ) 9,699,233 10,241,410 EVT-801 Licensing agreement - at cost 9,813,362 9,813,362 Less: Accumulated amortisation (1,308,448 ) (915,914 ) 8,504,914 8,897,448 18,204,147 19,138,858 Reconciliations Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below: EVT801 licensing agreement Restated* Paxalisib licensing agreement Total Consolidated $ $ $ Balance at 1 July 2022 8,897,448 10,241,410 19,138,858 Amortisation expense (392,534 ) (542,177 ) (934,711 ) Balance at 31 December 2022 8,504,914 9,699,233 18,204,147

Trade and other receivables - n

Trade and other receivables - non-current	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Trade and other receivables - non-current	Note 11. Trade and other receivables - non-current Consolidated December June 2022 2022 $ $ GBM Agile deposit 3,672,325 7,257,947 Corporate credit card deposit 42,923 42,923 3,715,248 7,300,870

Trade and other payables

Trade and other payables	6 Months Ended
	Dec. 31, 2022
Statement [line items]
Trade and other payables	Note 12. Trade and other payables Consolidated December June 2022 2022 $ $ Trade payables 2,306,921 1,524,174 Accrued and other payables 841,847 2,235,946 3,148,768 3,760,120

Borrowings

Borrowings	6 Months Ended
	Dec. 31, 2022
Borrowings [abstract]
Disclosure of borrowings [text block]	Note 13. Borrowings Consolidated December June 2022 2022 $ $ Insurance premium funding 552,315 —

Contingent consideration

Contingent consideration	6 Months Ended
	Dec. 31, 2022
Statement [line items]
Contingent consideration	Note 14. Contingent consideration Consolidated December June 2022 2022 Restated * $ $ Contingent consideration - Paxalisib 652,174 — Contingent consideration – EVT801 786,287 758,840 1,438,461 758,840 See also Note 16 setting out non-current contingent consideration.

Deferred tax

Deferred tax	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Deferred tax	Note 15. Deferred tax Consolidated December June 2022 2022 Restated * $ $ Deferred tax liability 2,424,815 2,560,361 Amount expected to be settled after more than 12 months 2,424,815 2,560,361 Movements: Opening balance 2,560,361 2,928,441 Credited to profit or loss (135,546 ) (368,080 ) Closing balance 2,424,815 2,560,361

Contingent consideration - non-

Contingent consideration - non-current	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Contingent consideration - non-current	Note 16. Contingent consideration - non-current Consolidated December June 2022 2022 Restated * $ $ Contingent consideration - Paxalisib 600,588 1,167,536 Contingent consideration - EVT801 7,517,729 7,041,409 8,118,317 8,208,945 A portion of the discount applied to anticipated future payments has unwound, with the resultant increase in contingent consideration being recognised in profit and loss. Consolidated December June 2022 2022 Restated * $ $ Reconciliation of the balance at the beginning and end of the reporting period is set out below: Contingent consideration at start of period (current and non-current) 8,967,785 11,094,441 Payment of EVT801 milestone — (2,364,732 ) Interest 221,637 414,662 Foreign currency loss 282,130 (328,873 ) Loss on revaluation of contingent consideration 85,226 152,287 9,556,778 8,967,785 Contingent consideration - paxalisib During the 2017 financial year, the consolidated entity acquired 100% of the issued shares in Glioblast Pty Ltd, a privately held, neuro-oncology-focused Australian biotechnology company. On the same day, Kazia entered into a worldwide licensing agreement with Genentech to develop and commercialise GDC-0084, now known as paxalisib. The Glioblast acquisition contains four contingent milestone payments, the first two milestone payments are to be settled with Kazia shares, and the third and fourth milestone payments are to be settled with either cash or Kazia shares at the discretion of Kazia. Milestones 1 and 4 have now been paid out, and Milestone 3 has lapsed. Milestone 2 comprises shares to the value of $1,250,000. The Genentech agreement comprises of one milestone payment payable on the first commercial licensed product sale, in the amount of $1,394,000. Each milestone payment is probability weighted for valuation purposes. The milestone payments are discounted to present value, using a discount rate of 15% (previously 35%) per annum. The discount rate was considered at 30 June 2021 and it was determined that the risk of the asset, and therefore of the milestones being met, has been considerably decreased as a result of paxalisib entering the pivotal GBM Agile trial, which is progressing well, and the license transaction with Simcere Pharmaceutical Group, which provides an external validation of paxalisib. Accordingly, the discount rate applied to future expected cash flows has been revised downwards. Kazia is also required to pay royalties to Genentech in relation to net sales. These payments are related to future financial performance, and are not considered as part of the consideration in relation to the Genentech agreement. Contingent consideration - EVT801 The acquisition of EVT801 has been accounted for at cost, with milestones where the payment is considered probable being booked as a current or non-current liability at period end, according to the estimated payment date. The milestone payments that have a probability of 100% are discounted to present value, using a discount rate of 6% per annum. The discount rate was considered based on the incremental borrowing rate at the time of acquisition. Milestones where the payment is not considered probable at year end have not been accounted for as a liability. The total amount of milestone payments not booked at year end amounts to €300,500,000 ($472,558,578).

Contributed equity

Contributed equity	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Contributed equity	Note 17. Contributed equity Consolidated December June 2022 December June 2022 2022 Restated * 2022 Restated * Shares Shares $ $ Ordinary shares - fully paid 163,408,976 138,755,376 90,343,718 84,480,249 19 Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 Note 17. Contributed equity (continued) Movements in spare share capital Details Date Shares Issue price $ Balance 1 July 2022 138,755,376 84,480,249 ATM issue of shares No. 8 7 July 2022 573,370 $ 0.7102 407,201 ATM issue of shares No. 9 8 August 2022 8,561,490 $ 0.3316 2,839,346 ATM issue of shares No. 10 9 August 2022 10,000 $ 0.2723 2,723 ATM issue of shares No. 11 10 August 2022 158,020 $ 0.2465 38,949 ATM issue of shares No. 12 11 August 2022 330,960 $ 0.2413 79,868 ATM issue of shares No. 13 12 August 2022 1,247,440 $ 0.2469 308,050 ATM issue of shares No. 14 12 September 2022 651,030 $ 0.2211 143,964 ATM issue of shares No. 15 13 September 2022 28,350 $ 0.2187 6,200 Scientific Advisory Board issue 14 September 2022 60,000 $ 0.2100 12,600 ATM issue of shares No. 16 7 October 2022 736,760 $ 0.1789 131,797 ATM issue of shares No. 17 28 October 2022 12,296,180 $ 0.1865 2,293,288 Less: share issue transaction costs — $ 0.0000 (400,517 ) Balance 31 December 2022 163,408,976 90,343,718 Share buy-back There is no current on-market share buy-back.

Dividends

Dividends	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Dividends	Note 18. Dividends There were no dividends paid, recommended or declared during the current or previous financial half-year.

Events after the reporting peri

Events after the reporting period	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Events after the reporting period	Note 19. Events after the reporting period On 3 January 2023 a deposit of US$428,096 was received from Labcorp Early Development Laboratories Inc. representing the refund due on the completion of the Paxalisib Phase II trial. On 16 January 2023 Kazia announced a placement to professional and sophisticated investors and the launch of an associated Share Purchase Plan for eligible shareholders. The placement of A$4,500,000, comprised of an unconditional placement of A$2,792,572 at $0.11 per share; and a conditional placement of A$1,707,428 at $0.11 per share, and was approved by shareholders at the Extraordinary General Meeting on 24 February 2023. Each placement was made to professional and sophisticated investors. The Placement was not underwritten. In addition, eligible shareholders were offered the opportunity to acquire up to A$30,000 of new shares through a Share Purchase Plan (SPP). All new shares issued under the Placement and the SPP ranked equally with the existing ordinary shares. Funding will be used to drive Kazia’s clinical program toward several critical inflection points through CY2023, including the final data read out on the paxalisib GBM AGILE study and for general working capital purposes. Funds raised by the SPP totalled A$2,606,000. No other matter or circumstance has arisen since 31 December 2022 that has significantly affected, or may significantly affect the consolidated entity’s operations, the results of those operations, or the consolidated entity’s state of affairs in future financial years.

Earnings per share

Earnings per share	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Earnings per share	Note 20. Earnings per share Consolidated December 2022 Consolidated December 2021 Restated* $ $ Loss after income tax attributable to the owners of Kazia Therapeutics Limited (13,586,027 ) (13,201,848 ) Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 145,661,097 132,014,383 Weighted average number of ordinary shares used in calculating diluted earnings per share 145,661,097 132,014,383 Cents Cents Basic earnings per share (9.327 ) (10.000 ) Diluted earnings per share (9.327 ) (10.000 ) 8,640,000 unlisted options have been excluded from the above calculations as they were anti-dilutive.

Reconciliation of loss after in

Reconciliation of loss after income tax to net cash used in operating activities	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Reconciliation of loss after income tax to net cash used in operating activities	Note 21. Reconciliation of loss after income tax to net cash used in operating activities Consolidated December 2022 $ December 2021 Restated* $ Loss after income tax benefit for the half-year (13,586,027 ) (13,201,848 ) Adjustments for: Depreciation and amortisation 934,741 934,711 Share—based payments 944,726 640,906 Foreign exchange differences 145,529 (40,536 ) Loss on contingent consideration 85,227 74,110 Contingent consideration interest 221,637 207,068 Change in operating assets and liabilities: Increase in trade and other receivables (650,153 ) (1,643,986 ) (Increase)/decrease in prepayments (628,404 ) 275,634 Decrease in GBM Agile deposit 3,836,630 — Increase in insurance premium funding 552,315 — (Decrease)/increase in trade and other payables (611,352 ) 1,608,366 Decrease in deferred tax liabilities (135,546 ) (315,974 ) Increase in employee benefits 84,529 70,139 Net cash used in operating activities (8,806,148 ) (11,391,410 )

Significant accounting polici_2

Significant accounting policies (Policies)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Basis of preparation	These general purpose financial statements for the interim half-year These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted	New or amended Accounting Standards and Interpretations adopted The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity.
Going concern	Going concern During the half year ended 31 December 2022 the consolidated entity experienced net cash outflows from operating activities of $8,806,148 (December 2021: $11,391,410) and incurred a loss after tax of $13,586,027 (December 2021 restated: $13,201,848). As at 31 December 2022 the consolidated entity had cash in hand and at bank of $4,390,523. The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. An ‘at-the-market’ equity program (ATM) with Oppenheimer & Co. Inc. (Oppenheimer), as sales agent was established in May 2022. Under the ATM, Kazia may offer and sell via Oppenheimer up to US$35 million of its ordinary shares, in the form of American Depository Shares (ADSs), with each ADS representing ten ordinary shares. Kazia entered into an Equity Distribution Agreement, dated 22 April 2022 (the Sales Agreement), with Oppenheimer, who acts as sales agent. As at 31 December 2022 net proceeds of A$9,560,357 have been raised. On 3 January 2023 a deposit of US$428,096 was received from Labcorp Early Development Laboratories Inc. representing the refund due on the completion of the Paxalisib Phase II trial. On 1 Accordingly the directors have prepared the financial statements on a going concern basis. While the Company’s current cash balance is not sufficient to fund the operations for a period of 12 months from the date of this report, the directors have prepared the financial statements on a going concern basis as they are confident of the Company’s ability to raise additional funding, via licensing and partnering activities, obtaining of grant funding or raising additional capital from investors. Should the above assumptions not prove to be appropriate, there is material uncertainty related to events or conditions that may cast significant doubt whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements.

Restatement of comparatives (Ta

Restatement of comparatives (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Schedule Of Material Restatement Of EVT 801 Asset	The error resulted in a material overstatement of the EVT-801 asset and a corresponding overstatement of the liability at acquisition. The impact of this error is noted below with the restated balances disclosed in note 10,14 and 16: 30 June 2022 Increase/ 30 June 2022 Restated Intangibles - licensing agreement EVT-801 10,857,763 (1,044,401 ) 9,813,362 Less Accumulated amortisation (1,049,555 ) 133,641 (915,914 ) 9,808,208 (910,760 ) 8,897,448 Current contingent consideration EVT-801 (758,840 ) — (758,840 ) Non-Current contingent consideration EVT-801 (7,588,405 ) 546,996 (7,041,409 ) (8,347,245 ) 546,996 (7,800,249 ) Net Assets 18,638,287 (363,764 ) 18,274,523 Accumulated losses (68,253,627 ) (363,764 ) (68,617,391 ) Total equity 18,638,287 (363,764 ) 18,274,523
Schedule Of Material Restatement Of Income Statement	Consolidated statement of profit and loss 31 December (Increase)/ 31 December Restated Research and development expense (Amortisation) (11,029,851 ) 41,776 (10,988,075 ) General and administrative expense (interest and foreign exchange impact) (2,261,366 ) (221,216 ) (2,482,582 ) Loss before tax (13,338,382 ) (179,440 ) (13,517,822 ) Income tax benefit 315,974 — 315,974 Loss after tax (13,022,408 ) (179,440 ) (13,201,848 ) Impact on basic and diluted earnings per share increase/(decrease) in earning per share Cents Cents Cents Basic loss for the year attributable to equity holders (9.864 ) (0.136 ) (10.000 ) Diluted loss for the year attributable to equity holders (9.864 ) (0.136 ) (10.000 )

Other income (Tables)

Other income (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of other income	Consolidated December 2022 December 2021 $ $ Government grants — 10,000 Bad debt recovery — 14,956 Other income — 24,956

Expenses (Tables)

Expenses (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of expenses	Consolidated December 2022 $ December 2021 Restated * $ Loss before income tax includes the following specific expenses: Amortisation Paxalisib licensing agreement 542,177 542,177 EVT-801 licensing agreement 392,534 392,534 Total amortisation 934,711 934,711 Interest expense Contingent consideration 221,637 207,068 Superannuation expense Defined contribution superannuation expense 63,734 93,960 Employee benefits expense excluding superannuation Employee benefits expense excluding superannuation 1,778,503 1,349,523

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of cash and cash equivalents	Consolidated December 2022 June 2022 $ $ Cash at bank and on hand 4,390,523 7,361,112

Trade and other receivables (Ta

Trade and other receivables (Tables)	6 Months Ended
	Dec. 31, 2022
Statement [line items]
Summary of current assets - trade and other receivables	Consolidated December 2022 June 2022 $ $ GST refundable 69,093 51,353 Paxalisib Phase II clinical trial refund 631,876 — 700,969 51,353 Deposit paid 40,159 39,622 741,128 90,975

Other Assets (Tables)

Other Assets (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of current assets - other	Consolidated December 2022 June 2022 $ $ Prepayments 784,557 156,153

Intangibles (Tables)

Intangibles (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of non-current assets - intangibles	Consolidated December 2022 June 2022 Restated * $ $ Paxalisib Licensing agreement - at acquired fair value 16,407,788 16,407,788 Less: Accumulated amortisation (6,708,555 ) (6,166,378 ) 9,699,233 10,241,410 EVT-801 Licensing agreement - at cost 9,813,362 9,813,362 Less: Accumulated amortisation (1,308,448 ) (915,914 ) 8,504,914 8,897,448 18,204,147 19,138,858
Summary of reconciliations of intangibles	Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below: EVT801 licensing agreement Restated* Paxalisib licensing agreement Total Consolidated $ $ $ Balance at 1 July 2022 8,897,448 10,241,410 19,138,858 Amortisation expense (392,534 ) (542,177 ) (934,711 ) Balance at 31 December 2022 8,504,914 9,699,233 18,204,147

Trade and other receivables -_2

Trade and other receivables - non-current (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of non-current assets - trade and other receivables non-current	Consolidated December June 2022 2022 $ $ GBM Agile deposit 3,672,325 7,257,947 Corporate credit card deposit 42,923 42,923 3,715,248 7,300,870

Trade and other payables (Table

Trade and other payables (Tables)	6 Months Ended
	Dec. 31, 2022
Statement [line items]
Summary of trade and other payables	Consolidated December June 2022 2022 $ $ Trade payables 2,306,921 1,524,174 Accrued and other payables 841,847 2,235,946 3,148,768 3,760,120

Borrowings (Tables)

Borrowings (Tables)	6 Months Ended
	Dec. 31, 2022
Borrowings [abstract]
Disclosure of detailed information about borrowings [text block]	Consolidated December June 2022 2022 $ $ Insurance premium funding 552,315 —

Contingent consideration (Table

Contingent consideration (Tables)	6 Months Ended
	Dec. 31, 2022
Statement [line items]
Summary of liabilities - contingent consideration	Consolidated December June 2022 2022 Restated * $ $ Contingent consideration - Paxalisib 652,174 — Contingent consideration – EVT801 786,287 758,840 1,438,461 758,840

Deferred tax (Tables)

Deferred tax (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of deferred taxes liability	Consolidated December June 2022 2022 Restated * $ $ Deferred tax liability 2,424,815 2,560,361 Amount expected to be settled after more than 12 months 2,424,815 2,560,361 Movements: Opening balance 2,560,361 2,928,441 Credited to profit or loss (135,546 ) (368,080 ) Closing balance 2,424,815 2,560,361

Contingent consideration - no_2

Contingent consideration - non-current (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of liabilities - contingent consideration	Consolidated December June 2022 2022 Restated * $ $ Contingent consideration - Paxalisib 600,588 1,167,536 Contingent consideration - EVT801 7,517,729 7,041,409 8,118,317 8,208,945
Summary of reconciliation of contingent consideration	Consolidated December June 2022 2022 Restated * $ $ Reconciliation of the balance at the beginning and end of the reporting period is set out below: Contingent consideration at start of period (current and non-current) 8,967,785 11,094,441 Payment of EVT801 milestone — (2,364,732 ) Interest 221,637 414,662 Foreign currency loss 282,130 (328,873 ) Loss on revaluation of contingent consideration 85,226 152,287 9,556,778 8,967,785

Contributed equity (Tables)

Contributed equity (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of equity - contributed equity	Consolidated December June 2022 December June 2022 2022 Restated * 2022 Restated * Shares Shares $ $ Ordinary shares - fully paid 163,408,976 138,755,376 90,343,718 84,480,249
Summary of movements in ordinary share capital	Movements in spare share capital Details Date Shares Issue price $ Balance 1 July 2022 138,755,376 84,480,249 ATM issue of shares No. 8 7 July 2022 573,370 $ 0.7102 407,201 ATM issue of shares No. 9 8 August 2022 8,561,490 $ 0.3316 2,839,346 ATM issue of shares No. 10 9 August 2022 10,000 $ 0.2723 2,723 ATM issue of shares No. 11 10 August 2022 158,020 $ 0.2465 38,949 ATM issue of shares No. 12 11 August 2022 330,960 $ 0.2413 79,868 ATM issue of shares No. 13 12 August 2022 1,247,440 $ 0.2469 308,050 ATM issue of shares No. 14 12 September 2022 651,030 $ 0.2211 143,964 ATM issue of shares No. 15 13 September 2022 28,350 $ 0.2187 6,200 Scientific Advisory Board issue 14 September 2022 60,000 $ 0.2100 12,600 ATM issue of shares No. 16 7 October 2022 736,760 $ 0.1789 131,797 ATM issue of shares No. 17 28 October 2022 12,296,180 $ 0.1865 2,293,288 Less: share issue transaction costs — $ 0.0000 (400,517 ) Balance 31 December 2022 163,408,976 90,343,718

Earnings per share (Tables)

Earnings per share (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Summary of earnings per share	Consolidated December 2022 Consolidated December 2021 Restated* $ $ Loss after income tax attributable to the owners of Kazia Therapeutics Limited (13,586,027 ) (13,201,848 ) Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 145,661,097 132,014,383 Weighted average number of ordinary shares used in calculating diluted earnings per share 145,661,097 132,014,383 Cents Cents Basic earnings per share (9.327 ) (10.000 ) Diluted earnings per share (9.327 ) (10.000 )

Reconciliation of loss after _2

Reconciliation of loss after income tax to net cash used in operating activities (Tables)	6 Months Ended
	Dec. 31, 2022
Text block [abstract]
Disclosure of reconciliation of profit or loss to operating cash flows	Consolidated December 2022 $ December 2021 Restated* $ Loss after income tax benefit for the half-year (13,586,027 ) (13,201,848 ) Adjustments for: Depreciation and amortisation 934,741 934,711 Share—based payments 944,726 640,906 Foreign exchange differences 145,529 (40,536 ) Loss on contingent consideration 85,227 74,110 Contingent consideration interest 221,637 207,068 Change in operating assets and liabilities: Increase in trade and other receivables (650,153 ) (1,643,986 ) (Increase)/decrease in prepayments (628,404 ) 275,634 Decrease in GBM Agile deposit 3,836,630 — Increase in insurance premium funding 552,315 — (Decrease)/increase in trade and other payables (611,352 ) 1,608,366 Decrease in deferred tax liabilities (135,546 ) (315,974 ) Increase in employee benefits 84,529 70,139 Net cash used in operating activities (8,806,148 ) (11,391,410 )

Significant accounting polici_3

Significant accounting policies - Additional Information (Detail)		6 Months Ended
	Jan. 16, 2023 AUD ($) $ / shares shares	Dec. 31, 2022 AUD ($)	Dec. 31, 2021 AUD ($)	Jan. 03, 2023 USD ($)	Jun. 30, 2022 AUD ($)	May 01, 2022 USD ($)	Jun. 30, 2021 AUD ($)
Disclosure of summary of significant accounting policies [line items]
Consolidated loss after income tax		$ 13,586,027	$ 13,201,848
Net cash outflows from operating activities		8,806,148	11,391,410
Consolidated cash in hand and at bank		4,390,523	15,188,957		$ 7,361,112		$ 27,586,760
Proceeds From Issuing Shares		5,850,869	$ 16,700
At The Market Equity Program [Member]
Disclosure of summary of significant accounting policies [line items]
Aggregate offering						$ 35,000,000
American Depository Shares [Member] | At The Market Equity Program [Member]
Disclosure of summary of significant accounting policies [line items]
Number of shares represented by one depositary receipt						10
Proceeds From Issuing Shares		$ 9,560,357
Deposit Recieved [Member] | Labcorp Early Development Laboratories Inc [Member]
Disclosure of summary of significant accounting policies [line items]
Deposits				$ 428,096
Major Ordinary Share Transactions [Member] | Share Purchase Plan [Member]
Disclosure of summary of significant accounting policies [line items]
Proceeds from issue of ordinary shares	$ 4,500,000
Major Ordinary Share Transactions [Member] | Share Purchase Plan [Member] | Unconditional Placement [Member]
Disclosure of summary of significant accounting policies [line items]
Proceeds from issue of ordinary shares	$ 2,792,572
Par value per share | $ / shares	$ 0.11
Major Ordinary Share Transactions [Member] | Share Purchase Plan [Member] | Conditional Placement [Member]
Disclosure of summary of significant accounting policies [line items]
Proceeds from issue of ordinary shares	$ 1,707,428
Par value per share | $ / shares	$ 0.11
Top of range [member] | Major Ordinary Share Transactions [Member] | Share Purchase Plan [Member]
Disclosure of summary of significant accounting policies [line items]
Number of shares issued | shares	30,000

Restatement of comparatives - S

Restatement of comparatives - Schedule of material restatement of financial position (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill	$ 18,204,147	$ 19,138,858
Contingent Consideration Current	1,438,461	758,840
Contingent Consideration Noncurrent	8,118,317	8,208,945
Contingent Consideration	9,556,778	8,967,785	$ 11,094,441
Net Assets	11,583,185	18,274,523
Accumulated losses	(82,199,932)	(68,617,391)
Total equity	11,583,185	18,274,523	$ 25,315,899	$ 37,853,195
Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Net Assets		18,638,287
Accumulated losses		(68,253,627)
Total equity		18,638,287		$ 37,850,719
Increase (decrease) due to corrections of prior period errors [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Net Assets		(363,764)
Accumulated losses		(363,764)
Total equity		(363,764)
Contingent consideration – EVT801 [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Contingent Consideration Current	786,287	758,840
Contingent Consideration Noncurrent	7,517,729	7,041,409
Contingent Consideration		(7,800,249)
Contingent consideration – EVT801 [Member] | Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Contingent Consideration Current		758,840
Contingent Consideration Noncurrent		7,588,405
Contingent Consideration		(8,347,245)
Contingent consideration – EVT801 [Member] | Increase (decrease) due to corrections of prior period errors [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Contingent Consideration Current		0
Contingent Consideration Noncurrent		546,996
Contingent Consideration		546,996
EVT801 Licensing Agreement [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill	8,504,914	8,897,448
EVT801 Licensing Agreement [Member] | Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		9,808,208
EVT801 Licensing Agreement [Member] | Increase (decrease) due to corrections of prior period errors [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		(910,760)
Gross carrying amount [member] | EVT801 Licensing Agreement [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		9,813,362
Gross carrying amount [member] | EVT801 Licensing Agreement [Member] | Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		10,857,763
Gross carrying amount [member] | EVT801 Licensing Agreement [Member] | Increase (decrease) due to corrections of prior period errors [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		(1,044,401)
Accumulated amortisation [member] | EVT801 Licensing Agreement [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill	$ (1,308,448)	(915,914)
Accumulated amortisation [member] | EVT801 Licensing Agreement [Member] | Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		(1,049,555)
Accumulated amortisation [member] | EVT801 Licensing Agreement [Member] | Increase (decrease) due to corrections of prior period errors [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		$ 133,641

Restatement of comparatives -_2

Restatement of comparatives - Schedule of material restatement of profit or loss and other comprehensive income (Detail) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Detailed Information about Material Restatement of Profit or Loss and Other Comprehensive Income [Line Items]
Research and development expense	$ (9,359,972)	$ (10,988,075)
General and administrative expense	(4,276,514)	(2,482,582)
Loss before tax	(13,721,573)	(13,517,822)
Income tax benefit	135,546	315,974
Loss after tax	$ (13,586,027)	$ (13,201,848)
Impact on basic and diluted earnings per share increase/(decrease) in earning per share
Basic loss for the year attributable to equity holders	$ (9.327)	$ (10)
Diluted loss for the year attributable to equity holders	$ (9.327)	$ (10)
Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Profit or Loss and Other Comprehensive Income [Line Items]
Research and development expense		$ (11,029,851)
General and administrative expense		(2,261,366)
Loss before tax		(13,338,382)
Income tax benefit		315,974
Loss after tax		$ (13,022,408)
Impact on basic and diluted earnings per share increase/(decrease) in earning per share
Basic loss for the year attributable to equity holders		$ (9.864)
Diluted loss for the year attributable to equity holders		$ (9.864)
Increase (decrease) due to corrections of prior period errors [Member]
Disclosure of Detailed Information about Material Restatement of Profit or Loss and Other Comprehensive Income [Line Items]
Research and development expense		$ 41,776
General and administrative expense		(221,216)
Loss before tax		(179,440)
Income tax benefit		0
Loss after tax		$ (179,440)
Impact on basic and diluted earnings per share increase/(decrease) in earning per share
Basic loss for the year attributable to equity holders		$ (0.136)
Diluted loss for the year attributable to equity holders		$ (0.136)

Restatement of comparatives - A

Restatement of comparatives - Additional Information (Detail)	Dec. 31, 2022
Restatement of comparatives [Abstract]
Incremental borrowing rate	6%

Other income - Summary of other

Other income - Summary of other income (Detail) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Material income and expense [abstract]
Government grant	$ 0	$ 10,000
Bad debt recovery	0	14,956
Other income	$ 0	$ 24,956

Expenses - Summary of expenses

Expenses - Summary of expenses (Detail) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure of expenses by nature [line items]
Amortisation	$ 934,711		$ 934,711
Interest expense
Contingent Consideration	221,637	$ 414,662	207,068
Superannuation expense
Defined contribution superannuation expense	63,734		93,960
Employee benefits expense excluding superannuation
Employee benefits expense excluding superannuation	1,778,503		1,349,523
Paxalisib licensing agreement [member]
Disclosure of expenses by nature [line items]
Amortisation	542,177		542,177
EVT801 Licensing Agreement [Member]
Disclosure of expenses by nature [line items]
Amortisation	$ 392,534		$ 392,534

Cash and cash equivalents - Sum

Cash and cash equivalents - Summary of Cash and Cash Equivalents (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Cash and cash equivalents [abstract]
Cash at bank and on hand	$ 4,390,523	$ 7,361,112

Trade and other receivables - S

Trade and other receivables - Summary of current assets - trade and other receivables (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Disclosure of financial assets [line items]
Trade and other receivables	$ 741,128	$ 90,975
GST Refundable [Member]
Disclosure of financial assets [line items]
Other current receivables	69,093	51,353
PaxalisibPhase II Clinical Trial Refund [Member]
Disclosure of financial assets [line items]
Other current receivables	631,876	0
Deposits Paid [Member]
Disclosure of financial assets [line items]
Other current receivables	40,159	39,622
Refundable [Member]
Disclosure of financial assets [line items]
Other current receivables	$ 700,969	$ 51,353

Trade and other receivables - A

Trade and other receivables - Additional Information (Detail)	Jan. 03, 2023 USD ($)
Labcorp Early Development Laboratories Inc [Member] | Deposit Recieved [Member]
Disclosure of financial assets [line items]
Deposits	$ 428,096

Other assets - Summary of curre

Other assets - Summary of current assets - other (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Statement of financial position [abstract]
Prepayments	$ 784,557	$ 156,153

Intangibles - Summary of non-cu

Intangibles - Summary of non-current assets - intangibles (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Disclosure of detailed information about intangible assets [line items]
Intangibles	$ 18,204,147	$ 19,138,858
Paxalisib Licensing agreement [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	9,699,233	10,241,410
Paxalisib Licensing agreement [member] | Gross carrying amount [member] | At fair value [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	16,407,788	16,407,788
Paxalisib Licensing agreement [member] | Accumulated amortisation [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	(6,708,555)	(6,166,378)
EVT801 licensing agreement [Member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	8,504,914	8,897,448
EVT801 licensing agreement [Member] | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles		9,813,362
EVT801 licensing agreement [Member] | Gross carrying amount [member] | At cost [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	9,813,362	9,813,362
EVT801 licensing agreement [Member] | Accumulated amortisation [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	$ (1,308,448)	$ (915,914)

Intangibles - Summary of reconc

Intangibles - Summary of reconciliations of intangibles (Detail) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 19,138,858
Amortisation expense	(934,711)	$ (934,711)
Ending balance	18,204,147
Paxalisib licensing agreement [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	10,241,410
Amortisation expense	(542,177)	(542,177)
Ending balance	9,699,233
EVT801 licensing agreement [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	8,897,448
Amortisation expense	(392,534)	$ (392,534)
Ending balance	$ 8,504,914

Trade and other receivables -_3

Trade and other receivables - non-current - Summary of non-current assets - trade and other receivables noncurrent (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Disclosure of detailed information about trade and other receivables noncurrent [line items]
Trade and other receivables - non-current	$ 3,715,248	$ 7,300,870
GBM agile deposit [member]
Disclosure of detailed information about trade and other receivables noncurrent [line items]
Trade and other receivables - non-current	3,672,325	7,257,947
Corporate credit card deposit [member]
Disclosure of detailed information about trade and other receivables noncurrent [line items]
Trade and other receivables - non-current	$ 42,923	$ 42,923

Trade and other payables - Summ

Trade and other payables - Summary of current liabilities - trade and other payables (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Trade and other payables [abstract]
Trade payables	$ 2,306,921	$ 1,524,174
Accrued And Other Payables	841,847	2,235,946
Total trade and other payables	$ 3,148,768	$ 3,760,120

Borrowings - Schedule of borrow

Borrowings - Schedule of borrowings (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Disclosure of detailed information about borrowings [line items]
Current borrowings	$ 552,315	$ 0
Insurance Premium Funding [Member]
Disclosure of detailed information about borrowings [line items]
Current borrowings	$ 552,315	$ 0

Contingent consideration - Summ

Contingent consideration - Summary of liabilities - contingent consideration (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Disclosure of contingent liabilities [line items]
Contingent Consideration Current	$ 1,438,461	$ 758,840
Contingent consideration - Paxalisib [Member]
Disclosure of contingent liabilities [line items]
Contingent Consideration Current	652,174	0
Contingent consideration – EVT801 [Member]
Disclosure of contingent liabilities [line items]
Contingent Consideration Current	$ 786,287	$ 758,840

Deferred tax - Summary of defer

Deferred tax - Summary of deferred taxes liability (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Deferred tax assets and liabilities [abstract]
Amount expected to be settled after more than 12 months	$ 2,424,815	$ 2,560,361
Credited to profit or loss	$ (135,546)	$ (368,080)

Contingent consideration - no_3

Contingent consideration - non-current - Summary of liabilities - contingent consideration (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Disclosure of contingent liabilities [line items]
Contingent consideration non current	$ 8,118,317	$ 8,208,945
Contingent consideration - Paxalisib [Member]
Disclosure of contingent liabilities [line items]
Contingent consideration non current	600,588	1,167,536
Contingent consideration – EVT801 [Member]
Disclosure of contingent liabilities [line items]
Contingent consideration non current	$ 7,517,729	$ 7,041,409

Contingent consideration - no_4

Contingent consideration - non-current - Summary of reconciliation of contingent consideration (Detail) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure In Tabular Form Of Changes In Contingent Consideration During The Period [Line Items]
Contingent Consideration	$ 8,967,785	$ 11,094,441
Interest	221,637	414,662	$ 207,068
Loss on revaluation of contingent consideration	85,226	152,287	74,110
Contingent Consideration	9,556,778	8,967,785	$ 11,094,441
Contingent consideration [member]
Disclosure In Tabular Form Of Changes In Contingent Consideration During The Period [Line Items]
Foreign currency loss	$ 282,130	(328,873)
EVT801 Licensing Agreement [Member]
Disclosure In Tabular Form Of Changes In Contingent Consideration During The Period [Line Items]
Payment of milestone		$ (2,364,732)

Contingent consideration - no_5

Contingent consideration - non-current - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2022 AUD ($) Milestone	Dec. 31, 2022 EUR (€) Milestone	Dec. 31, 2021	Jun. 30, 2017
Disclosure of contingent liabilities [line items]
Milestone payments not booked	$ 472,558,578	€ 300,500,000
Milestone payment discount rate	15%	15%	35%
Probability of milestone payments	100%	100%
Percentage of discount rate on milestone payments	6%	6%
Glioblast Pty Ltd [member]
Disclosure of contingent liabilities [line items]
Percentage of equity interests acquired				100%
Number of contingent milestone payments | Milestone	4	4
Genentech agreement [member]
Disclosure of contingent liabilities [line items]
Contingent consideration | $	$ 1,394,000
Number of contingent milestone payments | Milestone	1	1
Milestone Two [member]
Disclosure of contingent liabilities [line items]
Contingent consideration | $	$ 1,250,000

Contributed equity - Summary of

Contributed equity - Summary of movements in ordinary share capital (Detail) - AUD ($)

6 Months Ended

Dec. 31, 2022

Oct. 28, 2022

Oct. 07, 2022

Sep. 14, 2022

Sep. 13, 2022

Sep. 12, 2022

Aug. 12, 2022

Aug. 11, 2022

Aug. 10, 2022

Aug. 09, 2022

Aug. 08, 2022

Jul. 07, 2022

Dec. 31, 2022

Disclosure of classes of share capital [line items]

Beginning Balance

$ 18,274,523

Issue of shares

6,263,986

Ending balance

$ 11,583,185

$ 11,583,185

Contributed equity [member]

Disclosure of classes of share capital [line items]

Beginning Balance

138,755,376

Ending Balance

163,408,976

163,408,976

Beginning Balance

$ 84,480,249

Issue of shares

6,263,986

Ending balance

$ 90,744,235

90,744,235

Issued capital excluding issuance cost [Member]

Disclosure of classes of share capital [line items]

Beginning Balance

84,480,249

Ending balance

$ 90,343,718

$ 90,343,718

ATM issue of shares No. 8 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.7102

ATM issue of shares No. 8 [Member] | Contributed equity [member] | 7 July 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

573,370

Issue of shares

$ 407,201

ATM issue of shares No. 9 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.3316

ATM issue of shares No. 9 [Member] | Contributed equity [member] | 8 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

8,561,490

Issue of shares

$ 2,839,346

ATM issue of shares No. 10 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2723

ATM issue of shares No. 10 [Member] | Contributed equity [member] | 9 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

10,000

Issue of shares

$ 2,723

ATM issue of shares No. 11 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2465

ATM issue of shares No. 11 [Member] | Contributed equity [member] | 10 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

158,020

Issue of shares

$ 38,949

ATM issue of shares No. 12 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2413

ATM issue of shares No. 12 [Member] | Contributed equity [member] | 11 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

330,960

Issue of shares

$ 79,868

ATM issue of shares No. 13 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2469

ATM issue of shares No. 13 [Member] | Contributed equity [member] | 12 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

1,247,440

Issue of shares

$ 308,050

ATM issue of shares No. 14 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2211

ATM issue of shares No. 14 [Member] | Contributed equity [member] | 12 September 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

651,030

Issue of shares

$ 143,964

ATM issue of shares No. 15 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2187

ATM issue of shares No. 15 [Member] | Contributed equity [member] | 13 September 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

28,350

Issue of shares

$ 6,200

Scientific Advisory Board Issue [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.21

Scientific Advisory Board Issue [Member] | Contributed equity [member] | 14 September 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

60,000

Issue of shares

$ 12,600

ATM issue of shares No. 16 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.1789

ATM issue of shares No. 16 [Member] | Contributed equity [member] | 7 October 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

736,760

Issue of shares

$ 131,797

ATM issue of shares No. 17 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.1865

ATM issue of shares No. 17 [Member] | Contributed equity [member] | 28 October 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

12,296,180

Issue of shares

$ 2,293,288

Share issue transaction costs [member]

Disclosure of classes of share capital [line items]

Issue price

$ 0

Share issue transaction costs [member] | Contributed equity [member]

Disclosure of classes of share capital [line items]

Issue of shares

$ (400,517)

Contributed equity - Summary _2

Contributed equity - Summary of equity - contributed equity (Detail) - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Disclosure of classes of share capital [abstract]
Ordinary shares - fully paid, shares	163,408,976	138,755,376
Ordinary shares - fully paid	$ 90,343,718	$ 84,480,249

Events after the reporting pe_2

Events after the reporting period - Additional Information (Detail)		6 Months Ended
	Jan. 16, 2023 AUD ($) $ / shares	Dec. 31, 2022 AUD ($)	Jan. 03, 2023 USD ($)
Disclosure of non-adjusting events after reporting period [line items]
Issue of shares		$ 6,263,986
Major Ordinary Share Transactions [Member] | Share Purchase Plan [Member]
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from issue of ordinary shares	$ 4,500,000
Issue of shares	2,606,000
Major Ordinary Share Transactions [Member] | Share Purchase Plan [Member] | Top of range [member]
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued	30,000
Major Ordinary Share Transactions [Member] | Share Purchase Plan [Member] | Conditional Placement [Member]
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from issue of ordinary shares	$ 1,707,428
Par value per share | $ / shares	$ 0.11
Major Ordinary Share Transactions [Member] | Share Purchase Plan [Member] | Unconditional Placement [Member]
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from issue of ordinary shares	$ 2,792,572
Par value per share | $ / shares	$ 0.11
Labcorp Early Development Laboratories Inc [Member] | Deposit Recieved [Member]
Disclosure of non-adjusting events after reporting period [line items]
Deposits			$ 428,096

Earnings per share - Summary of

Earnings per share - Summary of earnings per share (Detail) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [abstract]
Loss after income tax attributable to the owners of Kazia Therapeutics Limited	$ (13,586,027)	$ (13,201,848)
Weighted average number of ordinary shares used in calculating basic earnings per share	145,661,097	132,014,383
Weighted average number of ordinary shares used in calculating diluted earnings per share	145,661,097	132,014,383
Basic earnings per share	$ (9.327)	$ (10)
Diluted earnings per share	$ (9.327)	$ (10)

Earnings per share - Additional

Earnings per share - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2022 shares
Unlisted options [member]
Earnings per share [line items]
Number of options that have been excluded from the calculations as they were antidilutive	8,640,000

Reconciliation of loss after _3

Reconciliation of loss after income tax to net cash used in operating activities - Disclosure of reconciliation of profit or loss to operating cash flows (Detail) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of profit or loss to operating cash flows [Line Items]
Loss after income tax benefit for the half-year	$ (13,586,027)	$ (13,201,848)
Adjustments for:
Depreciation and amortisation	934,741	934,711
Share—based payments	944,726	640,906
Foreign exchange differences	145,529	(40,536)
Loss on contingent consideration	85,227	74,110
Contingent consideration interest	221,637	207,068
Change in operating assets and liabilities: Increase in trade and other receivables	(650,153)	(1,643,986)
(Increase)/decrease in prepayments	(628,404)	275,634
Decrease in GBM Agile deposit	3,836,630
Increase in insurance premium funding	552,315
(Decrease)/increase in trade and other payables	(611,352)	1,608,366
Decrease in deferred tax liabilities	(135,546)	(315,974)
Increase in employee benefits	84,529	70,139
Net cash used in operating activities	$ (8,806,148)	$ (11,391,410)